The companies Thermo Fisher Scientific Inc. and Qiagen have announced that they agreed on amended terms to the acquisition agreement under which Thermo Fisher Scientific Inc. has commenced a tender offer to acquire all of the ordinary shares of Qiagen NV.
Pursuant to the amended terms, Thermo Fisher Scientific Inc. agrees to acquire all ordinary shares of Qiagen NV at the new offer price of EUR 43.00 per share. The acceptance period has been extended and is scheduled to expire on 10 August 2020.
More information about this transaction is available on the Thermo Fisher Scientific Inc. website www.ir.thermofisher.com.
The Eurex Corporate Action Info dated 03 March with respect to a possible fair-value settlement of options contracts, futures contracts and dividend futures contracts related to Qiagen NV is still applicable, though, the new offer price of EUR 43.00 would serve as reference price for a possible fair-value settlement.
On 13 August 2020, the company Thermo Fisher Scientific Inc. announced the result of the mandatory takeover to the shareholders of Qiagen NV at a price of EUR 43.00 per share.
The conditions of the offer are not fulfilled and the offer is therefore terminated. According the trading in contracts on Qiagen at Eurex will continue unchanged.